Changes in Pituitary Iron and Volume With Deferasirox
Despite continuing advances in iron chelation therapy, iron toxicity of endocrine glands, particularly the pituitary gland, remains common in patients with transfusion dependent anemias. We would like to establish accurate population norms of pituitary R2 and volume and understand the progression of pituitary iron in transfused patients on Deferasirox.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Changes in Pituitary Iron and Volume With Deferasirox in Transfusional Iron Overload|
|Study Start Date:||November 2008|
Chronically Transfusion Patients
Patients with transfusion dependent anemia (excluding sickle cell disease), ages 2-25, on Deferasirox chelation therapy, to be monitored over 2 years.
Normal controls, ages 2-25, with no known brain abnormality or endocrine dysfunction.
|United States, California|
|Children's Hospital Los Angeles|
|Los Angeles, California, United States, 90027|
|Principal Investigator:||John C Wood, MD, PhD||Children's Hospital Los Angeles|